Blood sequencing to find germs and predict outcomes in sepsis
Integrated Host-Microbe Metagenomics for Sepsis Pathogen Surveillance, Subphenotyping and Outcome Prediction
This project uses advanced blood sequencing on adults with septic shock to find the germs involved and the immune patterns that may predict outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11310119 on NIH RePORTER |
What this research studies
If you join, researchers will use blood and plasma samples collected from over 1,500 adults with septic shock enrolled in the CLOVERS trial. They will perform metagenomic sequencing to detect bacteria, viruses, and other microbes without relying on cultures, and measure host gene activity to capture immune responses. The team will combine microbial and host data to define sepsis subtypes and link them to clinical outcomes. The goal is to produce information that could help doctors identify infections faster and personalize treatments based on both the pathogen and the patient’s immune reaction.
Who could benefit from this research
Good fit: Ideal candidates are adults with septic shock whose blood or plasma can be obtained, typically patients treated at hospitals participating in the CLOVERS trial.
Not a fit: People without sepsis, children, and patients whose blood samples are not available or who are not treated at participating centers are unlikely to benefit directly.
Why it matters
Potential benefit: Could help doctors identify the cause of sepsis faster and predict which patients are most likely to worsen, guiding quicker, more targeted care.
How similar studies have performed: Earlier small studies show that metagenomic pathogen detection and host transcript profiling can identify infections and risk patterns, but combining both across a large septic shock cohort is relatively new.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Langelier, Charles — University of California, San Francisco
- Study coordinator: Langelier, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.